We can’t show the full text here under this license. Use the link below to read it at the source.
Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles
Engineered PsCas9 allows gene editing treatment in mouse liver using fat-based nanoparticles
AI simplified
Abstract
Engineered PsCas9 (ePsCas9) demonstrates up to 20-fold increased editing activity compared to its predecessor.
- PsCas9 is a Type II-B enzyme capable of editing the mouse liver genome with adenoviral delivery, showing no detectable off-target effects.
- Non-viral delivery of PsCas9 remains a challenge due to insufficient efficacy.
- Ribonucleoprotein structure of PsCas9 was solved using cryo-electron microscopy, aiding its rational engineering.
- Multiple guide RNA and protein variants were screened to develop ePsCas9, which retains safety advantages while enhancing activity.
- A single administration of mRNA encoding ePsCas9 with lipid nanoparticles achieved high editing levels in the Pcsk9 gene, relevant for hypercholesterolemia treatment.
AI simplified
Key numbers
20×
Increase in Editing Activity
ePsCas9 activity compared to wild-type PsCas9 across various targets.
60%
Editing Efficiency in Mouse Liver
Average editing efficiency in the Pcsk9 gene after ePsCas9 delivery.
10×
Off-Target Activity Reduction
ePsCas9 off-target activity compared to SpCas9.